163 related articles for article (PubMed ID: 36541733)
1. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
Dhillon SK; Cocuzza CE; Chung PYJ; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
J Med Virol; 2023 Jan; 95(1):e28417. PubMed ID: 36541733
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
Cocuzza CE; Dhillon SK; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
Int J Cancer; 2024 Feb; 154(3):538-547. PubMed ID: 37855030
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
[TBL] [Abstract][Full Text] [Related]
4. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.
Dhillon SK; Oštrbenk Valenčak A; Xu L; Poljak M; Arbyn M
J Clin Microbiol; 2021 May; 59(6):. PubMed ID: 33731413
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
7. Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
Bhatia R; Alcaniz Boada E; Bonde JH; Quint WGV; Xu L; Ejegod DM; Cuschieri K; Arbyn M
J Clin Pathol; 2023 Mar; 76(3):172-176. PubMed ID: 34782423
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.
Xu L; Oštrbenk Valenčak A; Poljak M; Arbyn M
J Clin Microbiol; 2020 May; 58(6):. PubMed ID: 32245832
[TBL] [Abstract][Full Text] [Related]
9. Clinical Evaluation of INNO-LiPA HPV Genotyping
Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Oštrbenk A; Xu L; Arbyn M; Poljak M
J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
[TBL] [Abstract][Full Text] [Related]
12. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
[TBL] [Abstract][Full Text] [Related]
13. Validation of EUROArray HPV test using the VALGENT framework.
Viti J; Poljak M; Oštrbenk A; Bhatia R; Alcañiz Boada E; Cornall AM; Cuschieri K; Garland S; Xu L; Arbyn M
J Clin Virol; 2018 Nov; 108():38-42. PubMed ID: 30223253
[TBL] [Abstract][Full Text] [Related]
14. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay.
Benoy I; Xu L; Vanden Broeck D; Poljak M; Oštrbenk Valenčak A; Arbyn M; Bogers J
J Clin Virol; 2019 Nov; 120():57-62. PubMed ID: 31569008
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
[TBL] [Abstract][Full Text] [Related]
17. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.
Heideman DA; Hesselink AT; van Kemenade FJ; Iftner T; Berkhof J; Topal F; Agard D; Meijer CJ; Snijders PJ
J Clin Microbiol; 2013 Nov; 51(11):3653-7. PubMed ID: 23985912
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.
Cuschieri K; Geraets DT; Moore C; Quint W; Duvall E; Arbyn M
J Clin Microbiol; 2015 Oct; 53(10):3272-9. PubMed ID: 26246482
[TBL] [Abstract][Full Text] [Related]
19. VALGENT: A protocol for clinical validation of human papillomavirus assays.
Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
